Low Estrogen Symptoms in Women: Drugs That Cause or Treat It

What Are the Symptoms of Low Estrogen in Women?

Low estrogen produces overlapping symptom clusters that span multiple organ systems. Hot flashes and night sweats are the most recognized, reported by up to 80% of perimenopausal women, but cognitive fog, joint pain, and cardiovascular changes are equally new for many patients. Recognizing the full spectrum matters because under-treated estrogen deficiency accelerates bone loss and raises long-term fracture risk.

Vasomotor Symptoms

Hot flashes are sudden sensations of heat, flushing, and sweating that last 1 to 5 minutes and may repeat dozens of times daily. The SWAN (Study of Women's Health Across the Nation) cohort study (N=3,302) found that moderate-to-severe vasomotor symptoms persisted for a median of 7.4 years from onset, far longer than previously assumed (1). Night sweats disrupt sleep architecture, contributing to fatigue and concentration difficulties.

Genitourinary Syndrome of Menopause (GSM)

GSM, the clinical term for vulvovaginal atrophy combined with urinary symptoms, affects approximately 50 to 60% of postmenopausal women yet remains under-reported (2). Symptoms include vaginal dryness, burning, dyspareunia, recurrent urinary tract infections, and urinary urgency. Unlike vasomotor symptoms, GSM does not resolve on its own and typically worsens over time without treatment.

Skeletal and Cardiovascular Changes

Estrogen maintains bone mineral density by suppressing osteoclast activity. In the first 5 years after menopause, trabecular bone loss accelerates to 2 to 3% per year, according to data from the WHI (Women's Health Initiative) (3). Estrogen also modulates vascular tone and lipid metabolism, so its loss shifts LDL cholesterol upward and reduces arterial elasticity.

Psychological and Cognitive Symptoms

Estrogen receptors are distributed throughout the brain, including the hippocampus and prefrontal cortex. Women in perimenopause report higher rates of depressive symptoms, anxiety, and verbal memory lapses. A 2019 meta-analysis in JAMA Psychiatry (N=9,141) found perimenopause was associated with a 40% higher odds of depressive symptoms compared with premenopause (OR 1.40, 95% CI 1.20 to 1.63, P<0.001) (4).

What Causes Low Estrogen in Women?

Estrogen levels fall when ovarian function declines or is suppressed, when the hypothalamic-pituitary axis is disrupted, or when specific drugs interfere with estrogen synthesis, receptor binding, or metabolism. The cause determines both the urgency of treatment and which therapy is appropriate.

Natural Menopause and Premature Ovarian Insufficiency

Natural menopause occurs at a median age of 51.4 years in U.S. Women. Premature ovarian insufficiency (POI), defined as ovarian failure before age 40, affects roughly 1% of women and carries added urgency because untreated hypoestrogenism at that age substantially increases osteoporosis and cardiovascular risk (5). POI causes include Turner syndrome, autoimmune destruction of follicles, and prior chemotherapy.

Surgical and Medical Causes

Bilateral oophorectomy produces immediate, abrupt estrogen loss. Compared with natural menopause, surgical menopause typically produces more severe vasomotor symptoms and a faster rate of bone loss. Hypothalamic amenorrhea, common in athletes and women with restrictive eating disorders, suppresses GnRH pulsatility and drives estrogen to prepubertal levels even in young women.

Hyperprolactinemia and Thyroid Dysfunction

Elevated prolactin, most often from a pituitary microadenoma or antipsychotic drug use, suppresses GnRH and secondary LH pulses, resulting in low estradiol. Severe hypothyroidism can also alter sex hormone-binding globulin (SHBG) concentrations and disturb the hypothalamic-pituitary-ovarian axis.

Which Drugs Cause Low Estrogen Symptoms in Women?

Several prescribed drug classes lower estrogen as either an intentional mechanism or an unintended side effect. Recognizing this drug-symptom link prevents misdiagnosis and unnecessary testing.

Aromatase Inhibitors (AIs)

Aromatase inhibitors, including anastrozole, letrozole, and exemestane, are prescribed for estrogen-receptor-positive breast cancer and certain conditions such as endometriosis or infertility. They block peripheral conversion of androgens to estrogens, driving serum estradiol to near-undetectable levels. In the ATAC trial (N=9,366), anastrozole reduced serum estradiol by over 96% versus placebo, which produced musculoskeletal pain in 35.6% of treated women, fractures in 11%, and substantial rates of vasomotor symptoms (6). These symptoms are expected and are directly caused by the drug's primary mechanism.

GnRH Agonists and Antagonists

Leuprolide, goserelin, buserelin, and elagolix suppress the hypothalamic-pituitary axis, producing a reversible medical menopause. Elagolix (Orilissa), a GnRH antagonist approved in 2018 for endometriosis, dose-dependently reduced serum estradiol: the 150 mg once-daily dose produced partial suppression (mean estradiol ~42 pg/mL), while the 200 mg twice-daily dose produced near-menopausal levels (mean ~12 pg/mL) in the key ARIES trials (7). Vasomotor symptoms, bone loss, and GSM occur predictably with higher-dose regimens.

Antidepressants, Antiepileptics, and Opioids

Certain selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) can raise prolactin levels and secondarily lower estrogen in susceptible women, though the magnitude is generally smaller than with GnRH agonists. Antiepileptic drugs such as carbamazepine, phenytoin, and valproate induce hepatic cytochrome P450 enzymes and increase SHBG, reducing free estradiol even when total estradiol appears normal (8). Chronic opioid use suppresses LH pulsatility through central mu-receptor activation, a mechanism well-documented in both pain management and opioid use disorder literature.

Progestins, Depot Medroxyprogesterone, and High-Dose Androgens

Depot medroxyprogesterone acetate (DMPA, Depo-Provera) suppresses ovarian estrogen production via gonadotropin inhibition. Studies show that prolonged DMPA use reduces lumbar spine bone mineral density by approximately 5 to 7% over 2 years in premenopausal women, a direct consequence of estrogen suppression (9). High-dose exogenous androgens (including some testosterone therapy protocols) can suppress the HPO axis similarly.

The table below summarizes the main drug classes, their mechanism of estrogen reduction, and the clinical threshold at which symptoms typically emerge.

| Drug Class | Example Agents | Mechanism | Estradiol Threshold for Symptoms | |---|---|---|---| | Aromatase inhibitors | Anastrozole, letrozole | Block androgen-to-estrogen conversion | <20 pg/mL | | GnRH agonists | Leuprolide, goserelin | Pituitary downregulation | <20 pg/mL | | GnRH antagonists | Elagolix, relugolix | Direct pituitary suppression | <30 pg/mL (dose-dependent) | | Antiepileptics | Carbamazepine, phenytoin | Increased SHBG, CYP450 induction | Variable (check free estradiol) | | Depot progestins | DMPA (Depo-Provera) | Gonadotropin suppression | <40 pg/mL | | Chronic opioids | Oxycodone, methadone | Central LH suppression | <30 pg/mL |

How Is Low Estrogen Diagnosed?

Diagnosis combines clinical assessment with targeted laboratory testing. No single test is sufficient in isolation, particularly in perimenopausal women where estrogen fluctuates widely day to day.

Laboratory Testing

The standard panel includes serum estradiol (E2), FSH, LH, and prolactin. An FSH persistently above 40 mIU/mL, combined with estradiol below 20 pg/mL, on two measurements taken at least 4 weeks apart, meets the diagnostic criteria for POI per the 2016 European Society of Human Reproduction and Embryology (ESHRE) guideline (10). Anti-Mullerian hormone (AMH) offers additional information about ovarian reserve in women with unclear diagnoses, though AMH is not a direct estrogen measure.

Testing should be timed carefully. Oral contraceptive pill users have suppressed FSH and falsely low estradiol on standard assays. Measurement should occur after a 6-week washout when clinically feasible.

Bone Density Assessment

DEXA scanning is recommended for any woman under 65 with low estrogen lasting more than 12 months. The U.S. Preventive Services Task Force (USPSTF) recommends osteoporosis screening for women under 65 who are at increased risk, which includes women with premature ovarian insufficiency (11).

When to Refer

Women with FSH and estradiol findings consistent with POI before age 40 should be referred to an endocrinologist or reproductive endocrinologist. A karyotype is indicated in women under 35 to rule out Turner syndrome mosaicism, found in up to 10% of POI cases.

Treatment Options for Low Estrogen in Women

Treatment selection depends on the underlying cause, the woman's age, symptom burden, bone density, and contraindications. Options range from systemic hormone therapy to non-hormonal drugs to localized vaginal preparations.

Systemic Hormone Therapy (HT)

Estrogen therapy is the most effective treatment for vasomotor symptoms. The Menopause Society 2023 Position Statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary symptoms of menopause and has been shown to prevent bone loss and fracture" (12). Women with a uterus require concurrent progestogen to protect the endometrium.

Common formulations include:

• Oral estradiol 0.5 mg to 2 mg daily
• Transdermal estradiol patches (0.025 mg to 0.1 mg per 24 hours)
• Estradiol gel or spray (0.25 mg to 1.5 mg daily)

The WHI Estrogen-Alone trial (N=10,739, mean age 63.6) found that conjugated equine estrogen 0.625 mg/day reduced hip fracture incidence by 30% and colorectal cancer by 37% in women who had undergone prior hysterectomy (13). Transdermal routes avoid first-pass hepatic metabolism, producing a lower clot risk than oral estrogen, a distinction that matters in women with borderline cardiovascular risk.

Vaginal Estrogen for GSM

Local vaginal estrogen preparations, including estradiol vaginal cream (Estrace), estradiol vaginal inserts (Vagifem, Yuvafem), the estradiol vaginal ring (Estring), and prasterone (Intrarosa, a vaginal DHEA), target GSM with minimal systemic absorption. A 2019 Cochrane review (30 trials, N=6,235) found that vaginal estrogen improved dyspareunia and dryness scores significantly more than placebo, with a standardized mean difference of 0.85 for patient-reported improvement (14). Ospemifene (Osphena), a selective estrogen receptor modulator taken orally at 60 mg daily, is an additional option for women who prefer not to use vaginal preparations.

Non-Hormonal Drug Treatments

For women with contraindications to estrogen therapy, specifically those with estrogen receptor-positive breast cancer or active thromboembolic disease, several non-hormonal options carry FDA approvals or strong clinical evidence:

• Fezolinetant (Veozah): A neurokinin 3 (NK3) receptor antagonist approved by the FDA in May 2023. The SKYLIGHT 1 trial (N=501) showed fezolinetant 45 mg/day reduced moderate-to-severe hot flash frequency by 60% from baseline at week 12 versus 34% for placebo (P<0.001) (15).
• Paroxetine 7.5 mg (Brisdelle): The only SSRI with an FDA-approved indication specifically for vasomotor symptoms, reducing hot flash frequency by approximately 33 to 67% in clinical trials.
• Venlafaxine 75 mg: Widely used off-label; a 2014 randomized trial published in JAMA (N=339) found venlafaxine reduced hot flash frequency by 48.9% versus 27.3% for placebo (16).
• Gabapentin 300 mg TID: Reduces hot flash frequency by approximately 45% in placebo-controlled studies, though sedation is a common limiting side effect.

Treating Drug-Induced Estrogen Suppression

When estrogen deficiency results from an AI or GnRH agonist used for a therapeutic purpose, the approach differs. Add-back therapy, meaning low-dose estradiol added to the GnRH agonist regimen, is supported by multiple trials for women on leuprolide for endometriosis and reduces bone loss without significantly reducing therapeutic efficacy (17). For AI-induced bone loss in breast cancer patients, bisphosphonates such as zoledronic acid 4 mg IV every 6 months are recommended by the American Society of Clinical Oncology guidelines.

Bone Protection: A Separate Priority

Addressing estrogen deficiency is not the same as addressing bone loss. Both may require separate management decisions, especially in women with POI or prolonged AI use.

Who Needs DEXA and When

The National Osteoporosis Foundation recommends DEXA at the time of POI diagnosis and every 1 to 2 years thereafter if treatment is not initiated. A T-score below negative 2.5 at any site meets criteria for osteoporosis and typically warrants pharmacological intervention regardless of estrogen status.

Bisphosphonates and RANKL Inhibitors

Alendronate 70 mg once weekly reduces vertebral fracture risk by approximately 50% in women with osteoporosis. Denosumab 60 mg subcutaneously every 6 months is an alternative for women with renal impairment who cannot tolerate bisphosphonates. Both agents can be combined with hormone therapy when the clinical picture warrants it.

Lifestyle Factors That Affect Estrogen Levels

Weight and body composition directly influence circulating estrogen. Adipose tissue is the primary site of peripheral estrogen synthesis via aromatase activity in postmenopausal women. A BMI below 18.5 kg/m² is associated with significantly lower estradiol and higher FSH across multiple cohort studies.

Regular moderate exercise preserves bone density and reduces vasomotor symptom severity in observational data, though it does not substitute for hormone therapy in women with moderate-to-severe symptoms. Smoking accelerates estrogen metabolism and is associated with earlier menopause by 1 to 2 years on average.

Dietary phytoestrogens, found in soy and flaxseed, bind estrogen receptors weakly but do not produce clinically meaningful reductions in FSH or increases in estradiol in controlled intervention studies. They may reduce hot flash frequency modestly, by 10 to 20%, but the effect is inconsistent across populations.